ImmunityBio (IBRX) announced new findings from the Phase 2 QUILT-3.055 study, presented at the IASLC 2025 World Conference on Lung Cancer. The study demonstrated that ANKTIVA reverses lymphopenia in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer. This reversal resulted in significant prolonged median overall survival. In patients with absolute lymphocyte counts greater than 1,500 cells/microL, a statistically significant prolonged median overall survival of 21.1 months was observed.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio’s Anktiva: A Promising Treatment for Long COVID?
- ImmunityBio’s Innovative Phase 2 Lymphoma Study: A Potential Game-Changer?
- ImmunityBio announces early findings from Anktiva pilot study
- ImmunityBio announces Anktiva trial
- ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment